Stock DRMA DERMATA THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Dermata Therapeutics, Inc.

Equities

DRMA

US2498453065

Market Closed - Nasdaq
Other stock markets
 04:30:00 2024-05-02 pm EDT 		5-day change 1st Jan Change
0.3401 USD +2.29% Intraday chart for Dermata Therapeutics, Inc. 0.00% -44.25%
Mar. 21 Dermata Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Jan. 05 Wall Street Set to Open Lower as Monthly Jobs Data Much Stronger Than Expected MT

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Dermata Therapeutics : Provides Corporate Update and Reports Full Year 2023 Financial Results - Form 8-K
PU
Dermata to Present at the Emerging Growth Conference on February 7, 2024
AQ
Dermata to Begin Enrolling Patients in DMT310 Phase 3 Acne Clinical Program in December 2023 based on Agreement with FDA on the Phase 3 Protocols
AQ
DERMATA THERAPEUTICS, INC. : Entry into a Material Definitive Agreement, Unregistered Sale of Equity Securities, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
AQ
Dermata Therapeutics awaits FDA go-ahead for lead candidate DMT310 to enter Phase 3 studies
AQ
CapitalGainsReport: CapitalGainsReport: Psychedelic Stock Watch (SILO, AITX, MNMD, DRMA)
AQ
DERMATA THERAPEUTICS, INC. : Other Events (form 8-K)
AQ
DERMATA THERAPEUTICS, INC. : Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
AQ
Dermata Therapeutics : Modification to Rights of Security Holders - Form 8-K
PU
DERMATA THERAPEUTICS, INC. : Material Modification to Rights of Security Holders, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits (form 8-K)
AQ
DERMATA THERAPEUTICS, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-K)
AQ
DERMATA THERAPEUTICS, INC. : Submission of Matters to a Vote of Security Holders (form 8-K)
AQ
DERMATA THERAPEUTICS, INC. : Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Other Events (form 8-K)
AQ
DERMATA THERAPEUTICS, INC. : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q)
AQ
DERMATA THERAPEUTICS, INC. : Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits (form 8-K)
AQ
Dermata Therapeutics : Provides Corporate Update and Reports Second Quarter 2022 Financial Results - Form 8-K
PU
DERMATA THERAPEUTICS, INC. : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q)
AQ
Dermata Therapeutics : Provides Corporate Update and Reports Second Quarter 2022 Financial Results
PU
DERMATA THERAPEUTICS, INC. : Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits (form 8-K)
AQ
DERMATA THERAPEUTICS, INC. : Change in Directors or Principal Officers (form 8-K)
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. DRMA Stock
  4. News Dermata Therapeutics, Inc.
  5. Press Releases